Lexicon Announces FDA Approval of Inpefa^TM (Sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that the US FDA approved INPEFA™, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.